Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Stephen Landy"'
Autor:
Andrew M. Blumenfeld, Richard B. Lipton, Stephen Silberstein, Stewart J. Tepper, Larry Charleston, Stephen Landy, Deena E. Kuruvilla, Aubrey Manack Adams
Publikováno v:
Neurology and Therapy, Vol 12, Iss 5, Pp 1533-1551 (2023)
Abstract Migraine is a neurologic disease with a complex pathophysiology that can be controlled with current treatment options but not cured. Therefore, treatment expectations are highly variable. The concept of migraine freedom was recently introduc
Externí odkaz:
https://doaj.org/article/bb3f6e1700ef433e92ce463429385b39
Autor:
Katie Kanter, Ryan Gallagher, Feyisope Eweje, Alexander Lee, David Gordon, Stephen Landy, Julia Gasior, Haideliza Soto-Calderon, Peter F. Cronholm, Ben Cocchiaro, James Weimer, Alexis Roth, Stephen Lankenau, Jacob Brenner
Publikováno v:
Harm Reduction Journal, Vol 18, Iss 1, Pp 1-14 (2021)
Abstract Background The incidence of opioid-related overdose deaths has been rising for 30 years and has been further exacerbated amidst the COVID-19 pandemic. Naloxone can reverse opioid overdose, lower death rates, and enable a transition to medica
Externí odkaz:
https://doaj.org/article/8fb9d846f1d941088f21b8446a4af4e7
Publikováno v:
The Journal of Headache and Pain, Vol 19, Iss 1, Pp 1-9 (2018)
Abstract Background In a previous randomized, double-blind, proof-of-concept study in rapidly escalating migraine, a 3 mg dose of subcutaneous sumatriptan (DFN-11) was associated with fewer and shorter triptan sensations than a 6 mg dose. The primary
Externí odkaz:
https://doaj.org/article/7f33fd9c1d6b45599aefd60becd8654f
Publikováno v:
The Journal of Headache and Pain, Vol 19, Iss 1, Pp 1-8 (2018)
Abstract Background DFN-11, a 3 mg sumatriptan subcutaneous (SC) autoinjector for acute treatment of migraine, has not been assessed previously in multiple attacks. The objective of this study was to evaluate the efficacy, tolerability, and safety of
Externí odkaz:
https://doaj.org/article/7f6277f70adf47a08afe2456a7511f80
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 6 (2013)
Objective: Efficacy and tolerability profiles of Treximet [sumatriptan/naproxen sodium combination tablet (SNC)] have been established in clinical trials but have to date been virtually unstudied in pragmatic research. The primary objective of this s
Externí odkaz:
https://doaj.org/article/ed061545f48b426ead4c4d2ec4c9211a
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 2 (2009)
A novel composite endpoint, sustained pain-free/no adverse events, was recently proposed as a more rigorous means of capturing in a single measure the attributes of migraine pharmacotherapy that patients consider most important: rapid and sustained p
Externí odkaz:
https://doaj.org/article/a488d5e1ee974fe28a15be1527545dc7
Autor:
Stephen Landy
Publikováno v:
New England Journal of Medicine. 388:1255-1257
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b0e59f74258c3b17c460f6bf3eacd0ae
https://doi.org/10.1056/nejmp2216655
https://doi.org/10.1056/nejmp2216655
Autor:
Alexis M. Roth, Stephen Landy, Jacob S. Brenner, Haideliza Soto-Calderon, Feyisope R. Eweje, Julia Gasior, Stephen E. Lankenau, Ryan Gallagher, Katie Kanter, Alexander Lee, Ben Cocchiaro, David Gordon, James Weimer, Peter F. Cronholm
Publikováno v:
Harm Reduction Journal
Harm Reduction Journal, Vol 18, Iss 1, Pp 1-14 (2021)
Harm Reduction Journal, Vol 18, Iss 1, Pp 1-14 (2021)
Background The incidence of opioid-related overdose deaths has been rising for 30 years and has been further exacerbated amidst the COVID-19 pandemic. Naloxone can reverse opioid overdose, lower death rates, and enable a transition to medication for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bbc136f6c91e03c022bce491fbe99bf
http://europepmc.org/articles/PMC8299455
http://europepmc.org/articles/PMC8299455
Publikováno v:
The Journal of Headache and Pain, Vol 19, Iss 1, Pp 1-8 (2018)
The Journal of Headache and Pain
The Journal of Headache and Pain
Background DFN-11, a 3 mg sumatriptan subcutaneous (SC) autoinjector for acute treatment of migraine, has not been assessed previously in multiple attacks. The objective of this study was to evaluate the efficacy, tolerability, and safety of DFN-11 i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07907a21146f5bed81d409936de7ba25
http://link.springer.com/article/10.1186/s10194-018-0882-y
http://link.springer.com/article/10.1186/s10194-018-0882-y
Publikováno v:
The Journal of Headache and Pain
The Journal of Headache and Pain, Vol 19, Iss 1, Pp 1-9 (2018)
The Journal of Headache and Pain, Vol 19, Iss 1, Pp 1-9 (2018)
Background In a previous randomized, double-blind, proof-of-concept study in rapidly escalating migraine, a 3 mg dose of subcutaneous sumatriptan (DFN-11) was associated with fewer and shorter triptan sensations than a 6 mg dose. The primary objectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9d37b081c26a936aeeda2e7d43f9a7f
http://europepmc.org/articles/PMC6093827
http://europepmc.org/articles/PMC6093827